Miraculins Inc.
TSX VENTURE : MOM

Miraculins Inc.

October 05, 2005 09:34 ET

Miraculins New CEO to Present Company at Major Biotech Conference

WINNIPEG, MANITOBA--(CCNMatthews - Oct. 5, 2005) - Miraculins Inc. (TSX VENTURE:MOM), a biotechnology company engaged in the discovery and development of biomarkers and diagnostics for select cancers, is pleased to announce that the Company will be providing a corporate update at BioContact in Quebec City, Quebec.

Dr. Vincent Lenaerts, Miraculins recently appointed President and CEO, will give his first corporate and scientific presentation of the Company on Friday, October 7, 2005 in the Salon Bellevue of the Chateau Frontenac Hotel. Dr. Lenaerts is scheduled to present at 9:30 am Eastern Time.

"I am looking forward to the opportunity provided by this important healthcare conference to present my vision for Miraculins," stated Dr. Lenaerts. "BioContact is an excellent forum for introducing the Company story to new investors and for updating our current shareholders".

BioContact is a leading biopharmaceutical partnering symposium, attracting over 1200 participants and 150 biopharmaceutical companies from North America and Europe.

About Miraculins Inc.

Miraculins is a biotechnology company focused on research and development using its proprietary BEST™ platform for the screening and identification of target proteins and peptides related to diseases. The Company is developing products for the diagnosis and treatment of select cancers. Its lead product focuses on improving the diagnosis of prostate cancer.

Prostate cancer is responsible for greater than 240,000 new diagnoses in North America each year. The current screening standard for prostate cancer, PSA, is ineffective at reliably distinguishing between non-life threatening prostate conditions and critical prostate cancer. In spite of this fact, there are greater than 25 million PSA tests performed annually in the United States alone, resulting in one million prostate biopsy procedures. An estimated 75% of these procedures are unnecessary and could be avoided if a superior alternative to PSA were available.

The Company continues to evaluate opportunities to expand its focus and initiate studies in additional disease conditions and recently initiated a study for the development of a diagnostic for breast cancer. Miraculins has also recently acquired a number of complimentary patents, creating opportunities for the Company in numerous additional cancer areas.

Certain information contained in this press release may be forward-looking and is subject to risks and uncertainties. Although the Company believes that the expectations contained herein are reasonable, it can give no assurances such forward-looking statements will prove correct. Information is provided from sources deemed to be reliable. The TSX Venture Exchange has neither approved nor disapproved the contents of this press release

Contact Information